The pharmacovigilance program on natalizumab in Italy: 2 years of experience
G. Tedeschi(Italian Medicines Agency), Gianluigi Mancardi(Istituti Clinici Scientifici Maugeri), Leandro Provinciali(Ospedali Riuniti di Ancona), Maria Giovanna Marrosu(University of Cagliari), Giovanni Savettieri(University of Palermo), Rosamaria Iommelli(Italian Medicines Agency), Luigi Grimaldi(Fondazione Istituto G. Giglio di Cefalù), Nicola Vanacore(Ministero della Salute), Antonio Addis(University of Toronto), Gıancarlo Comı(Casa di Cura Columbus), Maria Pia Amato(University of Florence), Filippo Drago(University of Catania), Nicola Montanaro(University of Bologna), Carlo Piccinni(University of Bologna), Carlo Pozzilli(Sapienza University of Rome), Anna Covezzoli(Cineca), Roberto D’Alessandro(Inserm), Paolo Rossi(Associazione Italiana Sclerosi Multipla), P. Popoli(Italian Medicines Agency), C. Milanese(Fondazione IRCCS Istituto Neurologico Carlo Besta), M. R. Tola(Vita-Salute San Raffaele University), Nello Martini(Italian Medicines Agency), Antonio Bertolotto(Neuroscience Institute), M. De Rosa(Cineca), Laura Periotto(Italian Medicines Agency)
Cited by 13
Related Papers
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Multiple Sclerosis Severity Score
|Neurology|2005|959
Genome-wide Analyses Identify KIF5A as a Novel ALS Gene
|Neuron|2018|724